nach oben

PharmacoEconomics

Erschienen in:

01.03.2001 | Original Research Article

Cost-Benefit Analysis of Active Vaccination Campaigns Against Hepatitis A Among Daycare Centre Personnel in Israel

verfasst von: Mr Gabriel Chodick, Yehuda Lerman, Tamar Peled, Hava Aloni, Shai Ashkenazi

Erschienen in: PharmacoEconomics | Ausgabe 3/2001

Einloggen, um Zugang zu erhalten

Abstract

Objective: To evaluate, in economic terms, active vaccination campaigns against hepatitis A in comparison with the use of nonspecific immune globulin for the prevention of the disease among daycare centre employees in Israel.

Setting: Hypothetical analysis of the costs and benefits related to vaccination campaigns of workers currently employed in daycare centres in Israel.

Methods: A cost-benefit analysis was performed, comparing mass and selective active vaccination strategies for the daycare centre working force. Direct and indirect costs of diagnosis, treatment and immunisation as well as productivity loss were considered. A Markov-based model was developed using data from previous epidemiological studies and literature.

Results: The benefit-to-cost ratios of selective and mass active vaccination strategies were 1.50 [net present value (NPV) $US606 396] and 0.04 (NPV-$US2.36 million), respectively (2000 values).

Conclusion: Under these study assumptions, the practice of administering hepatitis A active vaccine to serologically proven non-immune daycare centre workers has a cost-benefit justification, and should be widely considered in countries with a similar hepatitis A epidemiology to that in this study.

Gregorio GV, Mieli-Vergani G, Mowat AP. Viral hepatitis. Arch Dis Child 1994; 70 (4): 343–8PubMedCrossRef

Centers for Disease Control. Community-wide outbreaks of hepatitis A. Hepatitis surveillance report no. 51. Atlanta (GA): CDC, 1987: 6–8

Koff RS. Clinical manifestations and diagnosis of hepatitis A virus infection. Vaccine 1992; 10 Suppl. 1: S15–7PubMedCrossRef

Monthly epidemiologic record. Jerusalem: Department of Epidemiology — Israeli Ministry of Health, 1995 May-Dec

Green MS, Tsur S, Slepon R. Sociodemographic factors and the declining prevalence of anti-hepatitis A antibodies in young adults in Israel: implications for the new hepatitis A vaccines. Int J Epidemiol 1992; 21 (1): 136–41PubMedCrossRef

Karetnyi YV, Mendelson E, Shlyakhov E, et al. Prevalence of antibodies against hepatitis A virus among new immigrants in Israel. J Med Virol 1995; 46 (1): 61–5PubMedCrossRef

Hadler SC, McFarland L. Hepatitis in day care centres: epidemiology and prevention. Rev Infect Dis 1986; 8 (4): 548–57PubMedCrossRef

Reves RR, Pickering LK. Infections in child day care centres as they relate to internal medicine. Annu Rev Med 1990; 41: 383–91PubMedCrossRef

Lednar WM, Lemon SM, Kirkpatrick JW, et al. Frequency of illness associated with epidemic hepatitis A virus infection in adults. Am J Epidemiol 1985; 122: 226–33PubMed

10.

Jacques P, Moens G, Van Damme P, et al. Increased risk for hepatitis A among female day nursery workers in Belgium. Occup Med 1994; 44: 259–61CrossRef

11.

Lerman Y, Chodik G, Aloni H, et al. Occupations at increased risk of hepatitis A: a 2-year nationwide historical prospective study. Am J Epidemiol 1999; 150 (3): 312–20PubMedCrossRef

12.

Thomson JA, Kennedy R, Thompson SC. Hepatitis A vaccination of child care workers in Victoria: are recommendations being implemented? Aust N Z J Public Health 1998; 22 (7): 832–4PubMedCrossRef

13.

Labour Force Surveys 1993. Jerusalem: Central Bureau of Statistics, 1995

14.

Wiens B, Bohidar N, Pigeon J, et al. Duration of protection from clinical hepatitis A disease after vaccination with VAQTA. J Med Virol 1996; 49: 235–41PubMedCrossRef

15.

Lerman Y, Chodick G, Aloni H, et al. Is the health ministry official data valid? Hepatitis A as an example [in Hebrew]. Harefuha 1999; 136: 441–5

16.

Peled T, Lerman Y, Chodik G, et al. Sero prevalence of hepatitis A antibodies among day-care center workers. EPICOH, 14th International Conference on Epidemiology in Occupational Health; 1999 Oct 10–14; Herzlia

17.

Glikson M, Galun E, Oren R, et al. Relapsing hepatitis A: review of 14 cases and literature survey. Medicine 1992; 71: 14–23PubMed

18.

Plans Rubio P. Critical value of prevalence for vaccination programmes: the case of hepatitis A vaccination in Spain. Vaccine 1997; 15 (12–13): 1445–50PubMedCrossRef

19.

Van Damme P, Thoelen S, Cramm M, et al. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J Med Virol 1994; 44: 446–51PubMedCrossRef

20.

Polesky HF, Hanson MR. Comparison of viral hepatitis marker test methods based on AABB-CAP survey data. Am J Clin Pathol 1981; 76 (4 Suppl.): 521–4PubMed

21.

Ginsberg GM, Slater PE, Shouval D. Cost-benefit analysis of a nationwide infant immunization program against hepatitis A in an area of intermediate endemicity. J Hepatol. In press

22.

Jefferson TO, Behrens RH, Demicheli V. Should British soldiers be vaccinated against hepatitis A? An economic analysis. Vaccine 1994; 12 (15): 1379–83PubMedCrossRef

23.

Behrens RH, Roberts JA. Is travel prophylaxis worth while? Economic appraisal of prophylactic measures against malaria, hepatitis A, and typhoid in travelers. BMJ 1994 Oct 8; 309 (6959): 918–22PubMedCrossRef

24.

Arcari C, Shapiro C, Mast E, et al. An economic analysis of the use of hepatitis A vaccine to control community epidemics [abstract no. 277]. Clin Infect Dis 1996; 23: 911

25.

Smith S, Weber S, Wiblin T, et al. Cost-effectiveness of hepatitis A vaccination in healthcare workers. Infect Control Hosp Epidemiol 1997; 18 (10): 688–91PubMedCrossRef

26.

CDC vaccine price list [online]. Available from: URL: http://www.cdc.gov/nip/vfc/pricelist.pdf [Accessed 1999 Oct 26]

27.

Kark JD, Camhy NA, Shany SB. Reduction in hepatitis A antibody prevalence among young adults in Israel. Public Health Rev 1992-93; 20 (1–2): 31–40PubMed

28.

Vernon AA, Schable C, Francis D. A large outbreak of hepatitis A in a day-care center. Am J Epidemiol 1982; 115: 325–31PubMed

29.

Johannesson M, Jonsson B. Economic evaluation in health care: is there a role for cost-benefit analysis? Health Policy 1991; 17 (1): 1–23PubMedCrossRef

Titel: Cost-Benefit Analysis of Active Vaccination Campaigns Against Hepatitis A Among Daycare Centre Personnel in Israel
verfasst von: Mr Gabriel Chodick
Yehuda Lerman
Tamar Peled
Hava Aloni
Shai Ashkenazi
Publikationsdatum: 01.03.2001
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 3/2001
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.2165/00019053-200119030-00006

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Cost-Benefit Analysis of Active Vaccination Campaigns Against Hepatitis A Among Daycare Centre Personnel in Israel

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2001

Cost Effectiveness of Emedastine versus Levocabastine in the Treatment of Allergic Conjunctivitis in 7 European Countries

Rivastigmine

Influenza

Economic Burden of Chronic Obstructive Pulmonary Disease

Cost of Treatment for Onychomycosis

Cost-Effectiveness Analysis of Inhaled Zanamivir in the Treatment of Influenza A and B in High-Risk Patients